Difference between revisions of "Paroxysmal supraventricular tachycardia medical therapy"

Jump to: navigation, search
(Created page with "__NOTOC__ {{Paroxysmal supraventricular tachycardia}} {{CMG}}; {{AE}}{{Noha}}")
 
 
(One intermediate revision by the same user not shown)
Line 2: Line 2:
 
{{Paroxysmal supraventricular tachycardia}}
 
{{Paroxysmal supraventricular tachycardia}}
 
{{CMG}}; {{AE}}{{Noha}}
 
{{CMG}}; {{AE}}{{Noha}}
 +
==Overview==
 +
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
 +
 +
OR
 +
 +
Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
 +
 +
OR
 +
 +
The majority of cases of [disease name] are self-limited and require only supportive care.
 +
 +
OR
 +
 +
[Disease name] is a medical emergency and requires prompt treatment.
 +
 +
OR
 +
 +
The mainstay of treatment for [disease name] is [therapy].
 +
 +
OR
 +
 
 +
The optimal therapy for [malignancy name] depends on the stage at diagnosis.
 +
 +
OR
 +
 +
[Therapy] is recommended among all patients who develop [disease name].
 +
 +
OR
 +
 +
Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
 +
 +
OR
 +
 +
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
 +
 +
OR
 +
 +
Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
 +
 +
OR
 +
 +
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
 +
 +
==Medical Therapy==
 +
*Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
 +
*Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
 +
*Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
 +
*Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
 +
===Disease Name===
 +
 +
* '''1 Stage 1 - Name of stage'''
 +
** 1.1 '''Specific Organ system involved 1'''
 +
*** 1.1.1 '''Adult'''
 +
**** Preferred regimen (1): [[drug name]] 100 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)''' 
 +
**** Preferred regimen (2): [[drug name]] 500 mg PO q8h for 14-21 days
 +
**** Preferred regimen (3): [[drug name]] 500 mg q12h for 14-21 days
 +
**** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
 +
**** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
 +
**** Alternative regimen (3): [[drug name]] 500 mg PO q6h for 14–21 days
 +
*** 1.1.2 '''Pediatric'''
 +
**** 1.1.2.1 (Specific population e.g. '''children < 8 years of age''')
 +
***** Preferred regimen (1): [[drug name]] 50 mg/kg PO per day q8h (maximum, 500 mg per dose) 
 +
***** Preferred regimen (2): [[drug name]] 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
 +
***** Alternative regimen (1): [[drug name]]10 mg/kg PO q6h (maximum, 500 mg per day)
 +
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
 +
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
 +
****1.1.2.2 (Specific population e.g. '<nowiki/>'''''children < 8 years of age'''''')
 +
***** Preferred regimen (1): [[drug name]] 4 mg/kg/day PO q12h(maximum, 100 mg per dose)
 +
***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h (maximum, 500 mg per day)
 +
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose) 
 +
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
 +
** 1.2 '''Specific Organ system involved 2'''
 +
*** 1.2.1 '''Adult'''
 +
**** Preferred regimen (1): [[drug name]] 500 mg PO q8h
 +
*** 1.2.2  '''Pediatric'''
 +
**** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h (maximum, 500 mg per dose)
 +
 +
* 2 '''Stage 2 - Name of stage'''
 +
** 2.1 '''Specific Organ system involved 1 '''
 +
**: '''Note (1):'''
 +
**: '''Note (2)''':
 +
**: '''Note (3):'''
 +
*** 2.1.1 '''Adult'''
 +
**** Parenteral regimen
 +
***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
 +
***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
 +
***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
 +
**** Oral regimen
 +
***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
 +
***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
 +
***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
 +
***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
 +
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
 +
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
 +
*** 2.1.2 '''Pediatric'''
 +
**** Parenteral regimen
 +
***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
 +
***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
 +
***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) '<nowiki/>'''''(Contraindications/specific instructions)''''''
 +
**** Oral regimen
 +
***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
 +
***** Preferred regimen (2): [[drug name]] '''(for children aged ≥ 8 years)''' 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
 +
***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
 +
***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
 +
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
 +
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)
 +
** 2.2  '<nowiki/>'''''Other Organ system involved 2''''''
 +
**: '''Note (1):'''
 +
**: '''Note (2)''':
 +
**: '''Note (3):'''
 +
*** 2.2.1 '''Adult'''
 +
**** Parenteral regimen
 +
***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
 +
***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
 +
***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
 +
**** Oral regimen
 +
***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
 +
***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
 +
***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
 +
***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
 +
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
 +
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
 +
*** 2.2.2 '''Pediatric'''
 +
**** Parenteral regimen
 +
***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
 +
***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
 +
***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
 +
**** Oral regimen
 +
***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
 +
***** Preferred regimen (2): [[drug name]] 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
 +
***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
 +
***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
 +
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
 +
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)
 +
 +
==References==
 +
{{Reflist|2}}
 +
 +
 +
[[Category:Cardiology]]
 +
[[Category:Cardiovascular diseases]]
 +
[[Category:Arrhythmia]]
 +
[[Category:Emergency medicine]]
 +
[[Category:Disease]]
 +
[[Category:Up-To-Date]]
 +
[[Category:Up-To-Date cardiology]]
 +
 +
 +
{{WH}}
 +
{{WS}}

Latest revision as of 03:05, 24 May 2020

Paroxysmal supraventricular tachycardia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Paroxysmal supraventricular tachycardia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Paroxysmal supraventricular tachycardia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Paroxysmal supraventricular tachycardia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Paroxysmal supraventricular tachycardia medical therapy

CDC on Paroxysmal supraventricular tachycardia medical therapy

Paroxysmal supraventricular tachycardia medical therapy in the news

Blogs on Paroxysmal supraventricular tachycardia medical therapy

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Paroxysmal supraventricular tachycardia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Noha Elzeiny, M.B.B.Ch, M.Sc.[2]

Overview

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Medical Therapy

  • Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
  • Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
  • Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
  • Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Disease Name

  • 1 Stage 1 - Name of stage
    • 1.1 Specific Organ system involved 1
      • 1.1.1 Adult
        • Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days (Contraindications/specific instructions)
        • Preferred regimen (2): drug name 500 mg PO q8h for 14-21 days
        • Preferred regimen (3): drug name 500 mg q12h for 14-21 days
        • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
        • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
        • Alternative regimen (3): drug name 500 mg PO q6h for 14–21 days
      • 1.1.2 Pediatric
        • 1.1.2.1 (Specific population e.g. children < 8 years of age)
          • Preferred regimen (1): drug name 50 mg/kg PO per day q8h (maximum, 500 mg per dose)
          • Preferred regimen (2): drug name 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
          • Alternative regimen (1): drug name10 mg/kg PO q6h (maximum, 500 mg per day)
          • Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
          • Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
        • 1.1.2.2 (Specific population e.g. 'children < 8 years of age')
          • Preferred regimen (1): drug name 4 mg/kg/day PO q12h(maximum, 100 mg per dose)
          • Alternative regimen (1): drug name 10 mg/kg PO q6h (maximum, 500 mg per day)
          • Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
          • Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
    • 1.2 Specific Organ system involved 2
      • 1.2.1 Adult
        • Preferred regimen (1): drug name 500 mg PO q8h
      • 1.2.2 Pediatric
        • Preferred regimen (1): drug name 50 mg/kg/day PO q8h (maximum, 500 mg per dose)
  • 2 Stage 2 - Name of stage
    • 2.1 Specific Organ system involved 1
      Note (1):
      Note (2):
      Note (3):
      • 2.1.1 Adult
        • Parenteral regimen
          • Preferred regimen (1): drug name 2 g IV q24h for 14 (14–21) days
          • Alternative regimen (1): drug name 2 g IV q8h for 14 (14–21) days
          • Alternative regimen (2): drug name 18–24 MU/day IV q4h for 14 (14–21) days
        • Oral regimen
          • Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
          • Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
          • Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
          • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
          • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
          • Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
      • 2.1.2 Pediatric
        • Parenteral regimen
          • Preferred regimen (1): drug name 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
          • Alternative regimen (1): drug name 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
          • Alternative regimen (2):  drug name 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) '(Contraindications/specific instructions)'
        • Oral regimen
          • Preferred regimen (1): drug name 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
          • Preferred regimen (2): drug name (for children aged ≥ 8 years) 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
          • Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
          • Alternative regimen (1): drug name 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
          • Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
          • Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)
    • 2.2 'Other Organ system involved 2'
      Note (1):
      Note (2):
      Note (3):
      • 2.2.1 Adult
        • Parenteral regimen
          • Preferred regimen (1): drug name 2 g IV q24h for 14 (14–21) days
          • Alternative regimen (1): drug name 2 g IV q8h for 14 (14–21) days
          • Alternative regimen (2): drug name 18–24 MU/day IV q4h for 14 (14–21) days
        • Oral regimen
          • Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
          • Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
          • Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
          • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
          • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
          • Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
      • 2.2.2 Pediatric
        • Parenteral regimen
          • Preferred regimen (1): drug name 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
          • Alternative regimen (1): drug name 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
          • Alternative regimen (2):  drug name 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
        • Oral regimen
          • Preferred regimen (1): drug name 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
          • Preferred regimen (2): drug name 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
          • Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
          • Alternative regimen (1): drug name 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
          • Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
          • Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)

References




Linked-in.jpg